Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma

Radiotherapy and Oncology

Volumn 92, Issue 1, 2009, Pages 96-99

  Kristensen, Claus Andrup ^a   Nøttrup, Trine Juhler ^a   Berthelsen, Anne Kiil ^a   Kjær Kristoffersen, Flemming ^a   Ravn, Jesper ^a   Sørensen, Jens Benn ^a   Engelholm, Svend Aage ^a  

^a International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

Dose constraints; Extrapleural pneumonectomy; IMRT; Mesothelioma; Pulmonary toxicity

Indexed keywords

PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DYSPNEA; ESOPHAGITIS; FATALITY; FEMALE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG RESECTION; LUNG TOXICITY; MALE; MALIGNANT MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; PLEURA; PLEURA MESOTHELIOMA; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; THROMBOCYTOPENIA; VOMITING;

AGED; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; PNEUMONECTOMY; RADIATION DOSAGE; RADIATION PNEUMONITIS; RADIOTHERAPY, INTENSITY-MODULATED; TREATMENT OUTCOME;

EID: 66949173615     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.03.011     Document Type: Article

References (19)

1. Rusch V., Piantadosi S., and Holmes E.C. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. J Thorac Cardiovasc Surg 102 (1991) 1-9
2. Sugarbaker D.J., Flores R.M., Jaklitsch M.T., et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117 (1999) 54-63
3. Butchart E.G., Ashcroft T., Barnsley W.C., and Holden M.P. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax 31 (1976) 15-24
4. Rusch V.W. Indications for pneumonectomy. Extrapleural pneumonectomy. Chest Surg Clin N Am 9 (1999) 327-338
5. Sørensen J.B. Current concepts in chemotherapy for malignant pleural mesothelioma. Clin Respir J 3 (2008) 80-85
6. Baldini E.H., Recht A., Strauss G.M., et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 63 (1997) 334-338
7. Rusch V.W., Rosenzweig K., Venkatraman E., et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 122 (2001) 788-795
8. Allen A.M., Czerminska M., Jänne P.A., et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 65 (2006) 640-645
9. Rusch V.W. A proposed new international TNM staging system for malignant pleural mesothelioma from the international mesothelioma interest group. Lung Cancer 14 (1996) 1-12
10. Constine L.S., Williams J.P., Morris M., Rubin P., and Okunieff P. Late effects of cancer treatment on normal tissues. In: Perez C.A., Brady L.W., Halperin E.C., and Schmidt-Ullrich R.K. (Eds). Principles and practice of radiation oncology. 4th ed. (2004), Lippincott Williams & Wilkins, Philadelphia 357-390
11. Komaki R., Liao Z., Liu H., Tucker S., and Rice D. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma: in regard to Allen et al. Int J Radiat Oncol Biol Phys 66 (2006) 1595-1596
12. Rice D.C., Smythe W.R., Liao Z., et al. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 69 (2007) 350-357
13. Miles E.F., Larrier N.A., Kelsey C.R., et al. Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience. Int J Radiat Oncol Biol Phys 71 (2008) 1143-1150
14. Della Volpe A., Ferreri A.J.M.F., and Annaloro C. Lethal pulmonary complications significantly correlate with individually assessed mean lung dose in patients with hematologic malignancies treated with total body irradiation. Int J Radiat Oncol Biol Phys 52 (2002) 483-488
15. Seppenwoolde Y., Lebesque J.V., de Jaeger K., et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Int J Radiat Oncol Biol Phys 55 (2003) 724-735
16. Yorke E.D., Jackson A., Rosenzweig K.E., et al. Correlation of dosimetric factors and radiation pneumonitis for non-small cell lung cancer patients in a recently completed dose escalation study. Int J Radiat Oncol Biol Phys 63 (2005) 672-682
17. Wang S.L., Liao Z., Vaporciyan A.A., et al. Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 64 (2006) 692-699
18. Wu V.W.C., Kwong D.L.W., and Sham J.S.T. Target dose conformity in 3-dimensional conformal radiotherapy and intensity modulated radiotherapy. Radiother Oncol 71 (2004) 201-206
19. Allen A.M., Schofield D., Hacker F., Court L.E., and Czerminska M. Restricted field IMRT dramatically enhances IMRT planning for mesothelioma. Int J Radiat Oncol Biol Phys 69 (2007) 1587-1592